Menopause & Weight Loss
Can Wegovy Help Menopause Weight Gain?
Quick Answer: Wegovy may help with weight gain during menopause if you meet the usual clinical eligibility criteria. It is a weight-management medicine, not a treatment for menopause or its hormonal symptoms, and studies have not shown that it has a special effect on menopausal weight gain. In the STEP UP trial, adults with obesity who took 7.2 mg semaglutide lost an average of 20.7% of their starting weight over 72 weeks, compared with 17.5% at 2.4 mg. These were averages across the full study groups, so individual results vary. A prescriber should review your health, current medicines and HRT before treatment starts.0.25 mgusual weekly starting dose
2.4 mgusual weekly maintenance dose
20.7%average loss at 72 weeks with 7.2 mg in STEP UP
The Biology
Why Menopause Can Affect Weight
Many women notice that their weight or body shape changes during perimenopause and after menopause. Falling oestrogen can influence where fat is stored, with more weight tending to settle around the abdomen. Ageing, reduced muscle mass, sleep disruption and changes in activity can also lower daily energy needs.
This does not mean that weight gain is inevitable or that somebody has failed. It does mean that the approach which worked ten years ago may need adjusting. Before recommending treatment, I would look at the whole picture, including sleep, hot flushes, medicines, HRT, eating patterns, activity and any weight-related health conditions.
Important: Wegovy does not replace HRT and does not treat hot flushes, night sweats, low mood or other menopause symptoms. Its licensed role is weight management for people who meet the clinical criteria.
Appetite
Why Hunger Can Feel Different During Menopause
Poor sleep can make hunger and cravings harder to manage. Menopause can also coincide with a busy stage of life, less time for regular meals and a gradual loss of muscle. These factors often overlap, so there is rarely one single cause.
Wegovy contains semaglutide, which acts like the natural GLP-1 hormone. It reduces appetite, helps you feel full after smaller meals and slows the rate at which food leaves the stomach. This can make a reduced-calorie eating plan easier to follow, but it still works best alongside adequate protein, fibre, fluids and regular movement.
A Practical Approach
When Diet and Exercise Alone Have Not Been Enough
Some women arrive at the pharmacy feeling that they have tried everything. Often they have made sensible changes, but hunger, disrupted sleep or an unrealistic plan has made those changes difficult to sustain. The aim is not to eat as little as possible. It is to find a routine that helps limit muscle loss on Wegovy, supports health and can continue after the first few weeks.
- Build meals around a useful source of protein.
- Include vegetables, fruit and wholegrain foods for fibre.
- Use resistance exercise where it is safe and realistic.
- Review sleep problems and troublesome menopause symptoms with a clinician.
- Track trends over several weeks rather than reacting to a single weigh-in.
Treatment
How Wegovy Supports Weight Management
Treatment normally begins at 0.25 mg once weekly. The dose is increased over at least 16 weeks to reduce the chance of stomach and bowel side effects. The usual maintenance dose is 2.4 mg. A 7.2 mg dose may be considered for some adults with obesity after at least four weeks at 2.4 mg, but it is not the starting dose and is not suitable for everyone. See the full Wegovy dose schedule.
Less hungerSemaglutide acts on appetite centres in the brain.
Earlier fullnessSmaller meals may feel satisfying for longer.
Steady treatmentThe injection is taken once a week and increased gradually.
Evidence
What the Wegovy Trials Tell Us
The major semaglutide studies included many women, but they were not designed specifically to test menopause-related weight gain. The results below describe average changes across whole study groups and should not be read as a prediction for one person.
Results vary with dose, tolerability, starting weight, eating pattern, activity and how consistently treatment is used. A smaller loss can still improve health markers, and a prescriber should review both benefit and side effects.
| Study | Treatment | Average change | What to remember |
|---|---|---|---|
| STEP 1 | Semaglutide 2.4 mg | About 14.9% at 68 weeks | Adults with overweight or obesity, without diabetes |
| STEP UP | Semaglutide 7.2 mg | 20.7% at 72 weeks | Adults with obesity; not a menopause-specific trial |
| STEP UP | Semaglutide 2.4 mg | 17.5% at 72 weeks | Useful comparison within the same trial |
Health
Potential Benefits Beyond the Number on the Scales
These possible benefits depend on your health and risk factors. They do not mean Wegovy prevents every weight-related condition, and they are separate from treatment for menopause symptoms.
Waist measurementWeight loss often reduces waist circumference and abdominal fat.
Blood sugarSemaglutide can improve glucose control and insulin sensitivity.
MobilityLosing weight may make everyday movement and exercise more comfortable.
Cardiovascular riskWegovy reduced major cardiovascular events in a specific high-risk trial population.
Expectations
What Progress May Look Like
The first four months are mainly a dose-escalation period. Some people lose weight early, while others notice a clearer change after reaching a maintenance dose. I would usually look at the trend in weight, waist measurement, appetite, energy and side effects rather than judging treatment after one or two injections.
A plateau can happen as weight falls and the body needs less energy. It is a reason to review the plan, not to increase the dose without advice. Our Wegovy plateau advice covers the checks that can help.
Pharmacist tip: Keep meals regular enough to meet your nutritional needs. Persistent vomiting, severe abdominal pain, signs of dehydration or an inability to keep fluids down need prompt medical advice.
HRT
Can You Use Wegovy With HRT?
Many women use Wegovy and HRT at the same time. There is no blanket rule that HRT must be stopped, but your prescriber needs an accurate list of everything you take. This is particularly important if your HRT includes an oral progestogen.
Semaglutide slows stomach emptying. The clinical importance for oral HRT is still being assessed, so the safest approach is to ask the clinician who manages your HRT whether any change or extra monitoring is needed. Do not increase progesterone or switch HRT products yourself.
Speak to your GP or menopause specialist if you develop new or unexpected bleeding, if your HRT symptoms change, or if you are unsure whether the progesterone part of your HRT is oral. Weight loss itself may also change what feels comfortable or appropriate over time.
Safety
When to Speak to a Prescriber
A clinical assessment should cover your BMI, weight-related conditions, previous treatment, current medicines, pregnancy plans and relevant medical history. Menopause alone does not make somebody eligible for Wegovy.
- Ask for advice before starting if you use HRT, insulin or medicines that can cause low blood sugar.
- Tell the prescriber if you have had pancreatitis, gallbladder problems or severe digestive symptoms.
- Do not use Wegovy during pregnancy. Stop semaglutide at least two months before a planned pregnancy.
- Seek urgent help for severe and persistent abdominal pain, especially if it reaches through to the back.
FAQs
Frequently Asked Questions About Wegovy and Menopause
Wegovy may help an eligible person lose weight during or after menopause. It is not a menopause treatment, and current trials do not show a unique effect on weight caused specifically by menopause.
Yes, if you meet the usual weight-management criteria and a prescriber considers it suitable. Perimenopause itself is neither an indication nor a contraindication.
Many women use both. Tell both prescribers what you take, especially if your HRT contains an oral progestogen, and do not alter either treatment without advice.
Weight loss often reduces waist circumference and abdominal fat, but Wegovy cannot target one body area. Your response will depend on your overall weight change and body composition.
No. Wegovy is licensed for weight management and does not replace treatment for menopause symptoms. Speak to your GP or menopause clinician if those symptoms are affecting sleep or daily life.
Appetite may change during the first few weeks, but treatment starts at a low dose and builds gradually. Weight progress should be reviewed over several months alongside tolerability and health measures.
No. Suitability depends on BMI, weight-related health risks, medical history, other medicines and personal circumstances. An individual prescribing assessment is required.
Could Wegovy Be Suitable for You?
Complete our confidential online consultation. A UK prescriber will review your health, medicines and eligibility before any treatment is supplied.
Check Your Eligibility →
Sources: Wegovy 7.2 mg Summary of Product Characteristics | NICE TA875: Semaglutide for managing overweight and obesity | British Menopause Society: Use of incretin-based therapies. Educational information only; individual assessment is required.